Table 5.
Changes in the trend and level of utilisation estimated by ITS regression analysis.
| No. | Name | β0(p) | β1(p) | β2(p) | β3(p) | D-W |
|---|---|---|---|---|---|---|
| 1 | Rituximab | 529.49 (0.000) | 19.94 (0.032) | 737.89 (0.000) | 8.35 (0.587) | 1.95 |
| 2 | Trastuzumab | 838.27 (0.010) | 23.36 (0.371) | 760.11 (0.104) | −10.29 (0.817) | 2.00 |
| 3 | Bevacizumab | 854.03 (0.024) | 11.06 (0.715) | 2,628.39 (0.000) | 503.69 (0.000) | 1.93 |
| 4 | Sorafenib | 49.81 (0.492) | 5.68 (0.351) | 879.97 (0.000) | 12.94 (0.215) | 2.10 |
| 5 | Bortezomib | 139.72 (0.089) | 4.15 (0.538) | 632.05 (0.000) | 31.57 (0.009) | 1.93 |
| 6 | Erlotinib | 548.36 (0.000) | 2.05 (0.829) | 1,162.27 (0.000) | −0.55 (0.973) | 1.95 |
| 7 | Nimotuzumab | 486.04 (0.026) | −12.32 (0.466) | 425.78 (0.091) | 52.56 (0.094) | 2.14 |
| 8 | Apatinib | 23.0 (0.928) | 7.19 (0.728) | 334.31 (0.289) | 175.76 (0.000) | 1.97 |
| 9 | Everolimus | −4.04 (0.838) | 3.23 (0.057) | 33.19 (0.247) | −4.16 (0.152) | 2.00 |
| 10 | Recombinant human endostatin | 1,718.39 (0.000) | −12.11 (0.550) | 1,191.47 (0.002) | 54.76 (0.121) | 2.04 |